View More Recent Stories

Dec 6, 2021 08:00AM PharmaEssentia’s BESREMi® (ropeginterferon alfa-2b-njft) Now Available for the Treatment of People With Polycythemia Vera in the United States
Nov 12, 2021 06:23PM U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera
Oct 21, 2021 08:30AM PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting
Jun 3, 2021 02:07PM U.S. FDA Accepts PharmaEssentia’s BLA Resubmission for ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)
May 14, 2021 06:00AM PharmaEssentia Resubmits Application to the U.S. FDA For Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV)
Mar 14, 2021 12:30PM PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)
View More Recent Stories